Advertisement

Relation of Polymorphisms in Five Genes to Long-Term Aortocoronary Saphenous Vein Graft Patency

      Saphenous veins grafts (SVGs) continue to be used as conduits for coronary bypass surgery in nearly 350,000 patients annually in the United States. A possible genetic contribution to SVG longevity has not been well studied. We analyzed 168 single nucleotide polymorphisms from 150 candidate genes in 155 patients (2.1 SVGs/patient) followed for 10 ± 4 years who underwent coronary angiography for clinical indications. Age at coronary bypass was 54 ± 8 years, 61% were men, and 39% had diabetes mellitus. At the time of study entry, 76% were on statins. SVG patency (<70% diameter stenosis, no intervention), the primary study end point, was 60% at 5 years and 19% at 10 years. After adjustment for other factors associated with SVG patency (male gender, p = 0.007; low low-density lipoprotein, p = 0.016), 7 polymorphisms in 5 genes were associated with SVG patency (p <0.01). In conclusion, these data represent an initial step toward the use of a personalized genetic approach to coronary revascularization.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Loop F.D.
        • Lytle B.W.
        • Cosgrove D.M.
        • Goormastic S.M.
        • Williams G.W.
        • Golding L.A.
        • Gill C.C.
        • Taylor P.C.
        • Sheldon W.C.
        Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events.
        N Engl J Med. 1986; 314: 1-6
        • Thom T.
        • Haase N.
        • Rosamond W.
        • Howard V.J.
        • Rumsfeld J.
        • Manolio T.
        • Zheng Z.J.
        • Flegal K.
        • O’Donnell C.
        • Kittner S.
        • et al.
        • American Heart Association Statistics Committee and Stroke Statistics Subcommittee
        Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
        Circulation. 2006; 113: e85-e151
        • Goldman S.
        • Copeland J.
        • Moritz T.
        • Henderson W.
        • Zadina K.
        • Ovitt T.
        • Kern K.B.
        • Seithi G.
        • Sharma G.V.R.K.
        • Khuri S.
        • et al.
        Long-term graft patency (3 years) after coronary artery surgery: effects of aspirin: results of a VA Cooperative Study.
        Circulation. 1994; 89: 1138-1143
        • Gavaghan T.P.
        • Gebski V.
        • Baron D.W.
        Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery: a placebo-controlled, randomized study.
        Circulation. 1991; 83: 1526-1533
        • Domanski M.J.
        • Borkowf C.B.
        • Campeau L.
        • Knatterud G.L.
        • White C.
        • Hoogwerf B.
        • Rosenberg Y.
        • Geller N.L.
        Prognostic factors for atherosclerosis progression in saphenous vein grafts.
        J Am Coll Cardiol. 2000; 36: 1877-1883
        • Zotz R.B.
        • Klein M.
        • Dauben H.P.
        • Moser C.
        • Gams E.
        • Scharf R.E.
        Prospective analysis after coronary-artery bypass grafting; platelet GP IIIa polymorphism (HPA-1b/PIA2) is a risk factor for bypass occlusion, myocardial infarction, and death.
        Thrombosis Haemost. 2000; 83: 404-407
        • Moor E.
        • Silveira A.
        • van’t Hooft F.
        • Tornvall P.
        • Blomback M.
        • Wiman B.
        • Ryden L.
        • Hamsten A.
        Coagulation factor V (Arg506→Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting.
        Thrombosis Haemost. 1998; 80: 220-224
        • Mihai V.
        • Podgoreanu
        • Schwinn D.A.
        New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics.
        J Am Coll Cardiol. 2005; 46: 1965-1977
        • Ortlepp J.R.
        • Janssens U.
        • Bleckmann F.
        • Lauscher J.
        • Merkelbach-Bruse S.
        • Hanrath P.
        • Hoffmann R.
        A chymase gene variant is associated with atherosclerosis in venous coronary artery bypass grafts.
        Coron Artery Dis. 2001; 12: 493-497
        • Agah R.
        • Ellis S.G.
        • Chase S.
        • Henderson M.
        • Mlady L.
        • Murugesan G.
        • Tubbs R.
        • Marchant K.
        • Warshawsky I.
        • Rouse C.
        • et al.
        Creation of a large-scale genetic data bank for cardiovascular association studies.
        Am Heart J. 2005; 150: 500-506
        • Shiffman D.
        • Ellis S.G.
        • Rowland C.M.
        • Malloy M.J.
        • Luke M.M.
        • Iakoubova O.A.
        • Pullinger C.R.
        • Cassano J.
        • Aouizerat B.E.
        • Fenwick R.G.
        • et al.
        Identification of four gene variants associated with myocardial infarction.
        Am J Hum Genet. 2005; 77: 596-605
        • Li Y.
        • Tacey K.
        • Doil L.
        • van Luchene R.
        • Garcia V.
        • Rowland C.
        • Schrodi S.
        • Leong D.
        • Lau K.
        • Catanese J.
        • et al.
        Association of ABCA1 with late-onset Alzheimer’s disease is not observed in a case-control study.
        Neurosci Lett. 2004; 366: 268-271
        • Benjamini Y.
        • Hochberg Y.
        Controlling the false discovery rate: a practical and powerful approach to multiple testing.
        J R Stat Soc B. 1995; 57: 1289-1300
      1. Centers for Disease Control and Prevention. The 29th Report from the Health, United States Series. Available at: www.ncbi.nlm.nih.gov/entrez/query.

        • Fujita Y.
        • Yoshizumi M.
        • Izawa Y.
        • Ali N.
        • Ohnishi H.
        • Kanematsu Y.
        • Ishizawa K.
        • Tsuchiya K.
        • Tamaki T.
        Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation.
        Endocrinology. 2006; 147: 1377-1385
        • Kariyazono H.
        • Ohno T.
        • Khajoee V.
        • Ihara K.
        • Kusuhara K.
        • Kinukawa N.
        • Mizuno Y.
        • Hara T.
        Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease.
        Pediatr Res. 2004; 56: 953-959
        • Nikitina-Zake L.
        • Ghaderi M.
        • Park Y.
        • Babu S.
        • Eisenbarth G.
        • Sanjeevi C.B.
        MCIA gene polymorphism in HBDI multiplex families.
        Ann NY Acad Sci. 2004; 1037: 150-156
        • Torn C.
        • Gupta M.
        • Sanjeevi C.B.
        • Aberg A.
        • Frid A.
        • Landin-Olsson M.
        Different HL-DR-DQ and MHC class I chain-related gene a (MICA) genotypes in autoimmune and nonautoimmune gestational diabetes in a Swedish population.
        Hum Immunol. 2004; 65: 1443-1450
        • Chen M.
        • Jia G.
        • Luke M.M.
        • Liu D.M.
        • Topol E.J.
        • Lytle B.W.
        • Ellis S.G.
        Genomic association of graft failure of the left internal thoracic artery for myocardial revascularization.
        J Am Coll Cardiol. 2006; 47 (165A): 4
        • Rahman S.
        • Patel Y.
        • Murray J.
        • Patel K.V.
        • Sumathipala R.
        • Sobel M.
        • Wijelath E.S.
        Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signaling pathway in endothelial cells.
        BMC Cell Biol. 2005; 17: 6-8
        • Podor T.J.
        • Campbell S.
        • Chindemi P.
        • Foulon D.M.
        • Farrell D.H.
        • Walton P.D.
        • Weitz J.I.
        • Peterson C.B.
        Incorporation of vitronectin into fibrin clots.
        J Biol Chem. 2002; 277: 7520-7528
        • Ekmekei H.
        • Sonmez H.
        • Ekmekei O.B.
        • Ozturk Z.
        • Domanic N.
        • Kokoglu E.
        Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease.
        J Thromb Thrombolysis. 2002; 14: 221-225